Diagens Biotechnology Secures RMB 100 Million Series B Funding to Accelerate Expansion of Innovative Reproductive Health Products

Recently, VCBeat learned that Diagens, a leading upstream enterprise in the birth defect diagnosis and assisted reproduction industry, has successfully completed its Series B financing round. This round was jointly invested by Guozhong Capital, Jiangsu Huarui, Xiangjiang Liyuan, and Wuming Investment.

Hangzhou Diagens Biotechnology Co., Ltd. is a leading upstream enterprise in China’s healthy reproduction and assisted reproductive technology (ART) industry.Leveraging its proprietary core technologies and a top-tier team of industry experts, the company has successively launched core reproductive health products—including the world’s first AI-powered chromosomal diagnostic device, an internet-based genetic diagnosis platform, and innovative reproductive reagents and consumables—which have been widely recognized by clinical customers both in China and abroad.

Diagens, a national high-tech enterprise, is currently undertaking key national and provincial R&D programs. It has established a provincial-level R&D center for high-tech enterprises and formed an innovation-driven leading team composed of interdisciplinary high-level leading talents and professional technical experts.

Over the next two years, Diagens will collaborate with leading clinical centers and academic research institutions to expand its existing product portfolio. The company anticipates obtaining multiple approvals from China’s National Medical Products Administration (NMPA) as well as overseas regulatory certifications, thereby accelerating the market expansion of its innovative reproductive health products.

Dr. Song Ning, founder of Diagens, stated, “We are deeply grateful to both new and existing shareholders for their care and support of Diagens. In recent years, thanks to the concern and support of numerous clinical experts and the strong patronage of our extensive customer base, the company has forged an innovative path that closely aligns with actual clinical needs. By integrating basic and applied innovation, we have addressed core demands in reproductive medicine. Looking ahead, Diagens will further strengthen collaborations with clinical hospitals, universities, and research institutions, while enhancing the development of its R&D team. Through professionalized management, we aim to provide customers with high-quality, innovative products, reduce the incidence of birth defects, and improve both the quality and quantity of healthy births. Diagens is committed to contributing its strength to the healthy reproduction markets in China and overseas, ensuring a better legacy of life.”

Mr. Xie Bin, Vice President of Investment at Guozhong Capital, stated: “Diagens has pioneered global intelligent chromosome analysis, obtaining certification from China’s NMPA and the EU CE mark. Its solutions are now deployed in Grade 3A hospitals and assisted reproductive centers across China, significantly enhancing the efficiency of chromosome testing.”Meanwhile, Diagens has made in-depth strategic investments in the field of assisted reproductive reagents and consumables, and has been selected for the National Key R&D Program.“As a leading enterprise in the field of genetics and reproduction, Diagens aligns with China Guozhong Capital’s investment philosophy of deeply laying out the big health industry chain. China Guozhong is willing to join hands with Diagens to contribute to the construction of Healthy China.”

Mr. Wang Mangen, Founding Partner of Jiangsu Huarui Investment, stated: “Our investment in Diagens is based on three rationales,”FirstPrenatal diagnosis and assisted reproduction represent a major market segment. Promoting eugenics and healthy childbirth benefits both the nation and its people, aligning with national policy directions. Furthermore, as China’s population aging accelerates, the demand for assisted reproductive technologies will continue to rise. Currently, the assisted reproduction sector is dominated by foreign manufacturers, making domestic substitution in this field of greater strategic significance to the nation.Second, Diagens has a well-balanced combination of its internal management team and external expert advisors, possessing extensive experience and resources within the industry.Third, Diagens has accumulated significant technical expertise in its chromosomal testing products, offering distinct advantages over competitors and earning market recognition. In the field of core assisted reproductive technology products, we are confident that Diagens will become a leading industry player through independent innovation.”

Dr. You Xinnong, Chairman of Xiangjiang Liyuan, stated: “Guided by its original mission to ‘enable better inheritance of life,’ Diagens focuses on AI-based chromosomal diagnosis for birth defects and reagents and consumables for assisted reproduction. The company has achieved world-leading technological advantages in certain core products, which aligns closely with the national objective of optimizing fertility policies to promote long-term, balanced population development. We are delighted to support Diagens in achieving more substantial growth and better serving the nation’s strategic population initiatives.”

Mr. Zhang Zongyou, Partner at Wuming Investment, stated, “We are optimistic about Dr. Song Ning’s interdisciplinary academic background and his steadfast entrepreneurial spirit. By applying advanced AI technology to chromosomal karyotype analysis, the company’s third-generation intelligent chromosome analysis system has achieved global technological leadership, significantly enhancing the level of domestic production in this field. The fourth-generation online diagnostic system developed by the company redefines industry diagnostic models, substantially improving diagnostic efficiency in hospitals, and holds considerable economic and social value. We are delighted to join hands with Diagens to contribute to China’s reproductive health industry.”

Guozhong Capital currently manages two physical funds under the National SME Development Fund. Its subsidiary, Guozhong Venture Capital (Shenzhen Guozhong Venture Capital Management Co., Ltd.), manages the first physical fund of the National SME Development Fund, with a capital size of RMB 6 billion. Another subsidiary, Guozhong Changrong (Shenzhen Guozhong Changrong Asset Management Co., Ltd.), manages the Phase II fund of the National SME Development Fund, with a capital size of RMB 4 billion. The total assets under management have reached RMB 10 billion. Representative portfolio companies include Mindray Medical, DouYu, Jiayuan Technology, Zeltiq Pharmaceuticals, Rongchang Biopharma, Empyrean Technology, Huazhuo Jingke, Light Optoelectronics, Orient Semiconductor, Yahong Medicine, Shijia Photons, Hymson, and Ruoyuchen.

Jiangsu Huarui Investment was established in 2010. It manages nearly 20 fund products with assets under management approaching RMB 3 billion, and has successfully invested in more than 40 companies. The firm focuses on industry layout across three major industrial chains: TMT, automotive, and energy conservation and environmental protection, striving to provide professional equity investment services to its clients. Representative investment cases include: Vrv Software (300352.SZ), Anche Testing (300572.SZ), Tianneng Heavy Industries (300569.SZ), Foxit Software (688095.SH), Chengda Biopharm (688739.SH), Chengrui Optics, Runtai Technology, Xinxinteng, Longchuang Design, Jiangsu Guanlian, Maichi Shares, Huarui Micro, and Wellbest.

Xiangjiang Liyuan was established in 2014, with its core members hailing from China Merchants Xiangjiang Industrial Investment Management Co., Ltd. It is one of the first professional teams in China engaged in private equity investment. The core team has worked closely together for twenty years, cumulatively participating in the management of assets exceeding RMB 5 billion, and successfully exiting more than 30 projects through IPOs, mergers and acquisitions, private placements, and agreed transfers. Xiangjiang Liyuan focuses on the big health sector, extending its investment stage to early and mid-stage ventures, with a commitment to helping enterprises succeed. Since its establishment in 2014, its major investments include Hite Bio (300683), Nanxin Pharmaceutical (688189), Taihe Water (605081), Chongqing Shanwaishan, Shanghai Electric Kangda Medical, Shenzhen Shankang Medical, Hunan Tairui Medical, Chengdu Yitai Technology, Zhengqing Pharmaceutical, and Hunan Jinyi Environmental Protection.

Wuming Investment specializes in deep-value investing within the healthcare and medical industry, focusing on companies with unique competitive advantages and actively seeking entrepreneurial teams with a strong founder mentality. It has invested in numerous outstanding enterprises, including Mindray Medical (300760.SZ), Luoxin Pharmaceutical (002793.SZ), Boji Medicine (300404.SZ), Fuxiang Shares (300497.SZ), and Guangshengtang (300436.SZ), achieving comprehensive coverage in the healthcare sector and creating significant social value.